At a glance
- Originator Aventis
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Hyperlipidaemia
Most Recent Events
- 20 Feb 1995 Discontinued-Preclinical for Diabetes mellitus in USA (Unknown route)
- 20 Feb 1995 Discontinued-Preclinical for Hyperlipidaemia in USA (Unknown route)